Chimeric antigen receptor T cell therapies for thoracic cancers-challenges and opportunities

JD Chan; AJ Harrison; PK Darcy; MH Kershaw; CY Slaney

Journal article

Chimeric antigen receptor T cell therapies for thoracic cancers-challenges and opportunities

JD Chan, AJ Harrison, PK Darcy, MH Kershaw, CY Slaney

Journal of Thoracic Disease | AME PUBLISHING COMPANY | Published : 2020

DOI: 10.21037/jtd.2020.03.34

Open access

Download PDF

Abstract

Chimeric antigen receptor T cell therapies for thoracic cancers— challenges and opportunities

University of Melbourne Researchers

Phillip Darcy Author

Clare Slaney Author

Related Projects (6)

CAR T CELLS AND "A GOOD BEATING" FOR CANCER THERAPY

A promising T cell cancer immunotherapy involves an injection of a patient’s own T cells that have been modified to have an anti-cancer mole..

ADOPTIVE CELL TRANSFER INCORPORATING VACCINATION (ACTIV) THERAPY FOR CANCER

We have made a breakthrough in a new treatment for cancer that can destroy large tumours in mice. The treatment involves a transfusion of wh..

IMMUNOBIOLOGY AND IMMUNOTHERAPY OF CANCER

For 60 years, we have had only 3 effective cancer treatments: surgery, radiation and chemotherapy, often used in combination.The last 5 year..

USING LESSONS FROM TOXIC SHOCK SYNDROME TO ENHANCE BREAST CANCER IMMUNOTHERAPY

TARGETING BREAST CANCER USING ADOPTIVE CELL TRANSFER INCORPORATING VACCINATION

Chimeric antigen receptor (CAR) T cell therapy is a novel form of adoptive cellular therapy and has recently generated remarkable effects in..

CAR T CELLS AND A GOOD \201CBEATING\201D FOR BREAST CANCERS

Grants

Awarded by Susan G. Komen

Funding Acknowledgements

This work was supported by grants from the Peter MacCallum Cancer Centre Foundation, the National Health and Medical Research Council (NHMRC) of Australia (1176935, 1103352 and 1132373), the National Breast Cancer Foundation (NBCF) of Australia (IIRS-18064 and IIRS-20-073) and Susan G. Komen Breast Cancer Foundation (16376637). JDC was supported by a Research Training Program (RTP) and Rosie Lew scholarships. PKD and MHK were supported by NHMRC Senior Research Fellowships. CYS was supported by a Postdoctoral Fellowship from the NBCF.